Tim joined Karus as Executive Chairman in 2018. He has extensive management and advisory experience in the biopharmaceutical industry. As well as his role at Karus, Tim is a Director of Ervaxx Limited, a privately-held company developing first-in-class cancer vaccines, incubated by SV Health Investors; and Chair of Storm Therapeutics Limited, working in the field of RNA epigenetics, leveraging insights from the Gurdon Institute, Cambridge. He is also a Non-executive Director of Record PLC, a leading currency management firm; a Trustee of the Institute for Research in Schools; a Governor of Magdalen College School, Oxford; and a Fellow of the RSA, a charity founded in 1754 which drives ideas, innovation and social change.
Previously Tim was a Director and COO of TRex Bio Limited, another of SV Health Investors’ portfolio companies, which is developing the next generation of Regulatory T cell modulators in San Francisco. He was also Chairman of Atopix Therapeutics Limited, acquired by Chiesi Farmaceutici SpA in 2016; President and CEO of Cellzome Inc., acquired by GlaxoSmithKline plc in 2012; a Governing Board member of InnovateUK, the UK’s innovation agency; a Non-Executive Director of the Cell Therapy Catapult; and Chair of the UK BioIndustry Association.